CN114555638B - 结合4-1bb的抗体及其用途 - Google Patents

结合4-1bb的抗体及其用途 Download PDF

Info

Publication number
CN114555638B
CN114555638B CN202080071050.2A CN202080071050A CN114555638B CN 114555638 B CN114555638 B CN 114555638B CN 202080071050 A CN202080071050 A CN 202080071050A CN 114555638 B CN114555638 B CN 114555638B
Authority
CN
China
Prior art keywords
seq
antibody
chain variable
variable region
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080071050.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN114555638A (zh
Inventor
康小强
黄潇
孙建明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Weilizibo Biotechnology Co ltd
Original Assignee
Nanjing Wei Li Zhi Bo Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Wei Li Zhi Bo Biotechnology Co ltd filed Critical Nanjing Wei Li Zhi Bo Biotechnology Co ltd
Priority to CN202311290309.4A priority Critical patent/CN117586400A/zh
Publication of CN114555638A publication Critical patent/CN114555638A/zh
Application granted granted Critical
Publication of CN114555638B publication Critical patent/CN114555638B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080071050.2A 2019-10-11 2020-09-30 结合4-1bb的抗体及其用途 Active CN114555638B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311290309.4A CN117586400A (zh) 2019-10-11 2020-09-30 结合4-1bb的抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913744P 2019-10-11 2019-10-11
US62/913,744 2019-10-11
PCT/CN2020/119388 WO2021068841A1 (en) 2019-10-11 2020-09-30 Antibodies binding 4-1bb and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311290309.4A Division CN117586400A (zh) 2019-10-11 2020-09-30 结合4-1bb的抗体及其用途

Publications (2)

Publication Number Publication Date
CN114555638A CN114555638A (zh) 2022-05-27
CN114555638B true CN114555638B (zh) 2023-08-22

Family

ID=75382666

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080071050.2A Active CN114555638B (zh) 2019-10-11 2020-09-30 结合4-1bb的抗体及其用途
CN202311290309.4A Pending CN117586400A (zh) 2019-10-11 2020-09-30 结合4-1bb的抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311290309.4A Pending CN117586400A (zh) 2019-10-11 2020-09-30 结合4-1bb的抗体及其用途

Country Status (5)

Country Link
US (2) US11466086B2 (https=)
EP (1) EP4041772A4 (https=)
JP (2) JP7634001B2 (https=)
CN (2) CN114555638B (https=)
WO (1) WO2021068841A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7634001B2 (ja) * 2019-10-11 2025-02-20 ナンチン リーズ バイオラブス カンパニー，リミティド ４－１ｂｂに結合する抗体およびその用途
CN116253799B (zh) * 2021-09-09 2024-04-26 广东东阳光药业股份有限公司 抗4-1bb的激动型抗体及其应用
WO2023168547A1 (en) * 2022-03-07 2023-09-14 Adagene Pte. Ltd. Anti-cd137 antibodies and methods of making and using the same
WO2024051752A1 (en) * 2022-09-06 2024-03-14 I-Mab Biopharma Co., Ltd. Multispecific constructs and uses thereof
JP2026508244A (ja) 2023-02-22 2026-03-10 ナンジング リーズ バイオラブズ シーオー．， エルティーディー． 抗Ｎｅｃｔｉｎ－４抗体及びそれを含む多重特異性抗体
AU2024352742A1 (en) * 2023-09-27 2026-04-09 Nanjing Leads Biolabs Co., Ltd. Anti-pd-l1 and anti-4-1bb bispecific antibody for treating tumors
CN117736330B (zh) * 2024-01-24 2024-05-17 上海沙砾生物科技有限公司 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用
WO2026061538A1 (zh) * 2024-09-23 2026-03-26 南京维立志博生物科技股份有限公司 用于治疗恶性肿瘤的抗pd-l1和抗4-1bb双特异性抗体及其药物组合

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016134358A1 (en) * 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137
WO2017123650A2 (en) * 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins
WO2018156740A1 (en) * 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
CN109021107A (zh) * 2018-09-05 2018-12-18 江苏诺迈博生物医药科技有限公司 一种特异性结合人pd-l1的单克隆抗体及包含其的药物和试剂盒
EP3470426A1 (en) * 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
CN109762066A (zh) * 2017-11-09 2019-05-17 上海开拓者生物医药有限公司 4-1bb抗体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN114181309B (zh) * 2015-05-21 2024-07-30 鳄鱼生物科学公司 新型多肽
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
ES2981272T3 (es) * 2016-09-23 2024-10-08 Merus Nv Moléculas de unión que modulan una actividad biológica expresada por una célula
SG11202000198QA (en) * 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
US12202911B2 (en) 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
FI3830120T3 (fi) 2018-07-31 2023-06-13 Pieris Pharmaceuticals Gmbh CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini
JP7575100B2 (ja) 2018-11-13 2024-10-29 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫細胞活性化のための二重特異性抗体
CN113286825B (zh) 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途
JP7634001B2 (ja) * 2019-10-11 2025-02-20 ナンチン リーズ バイオラブス カンパニー，リミティド ４－１ｂｂに結合する抗体およびその用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016134358A1 (en) * 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137
WO2017123650A2 (en) * 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins
WO2018156740A1 (en) * 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
EP3470426A1 (en) * 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
CN109762066A (zh) * 2017-11-09 2019-05-17 上海开拓者生物医药有限公司 4-1bb抗体及其制备方法和应用
CN109021107A (zh) * 2018-09-05 2018-12-18 江苏诺迈博生物医药科技有限公司 一种特异性结合人pd-l1的单克隆抗体及包含其的药物和试剂盒

Also Published As

Publication number Publication date
CN117586400A (zh) 2024-02-23
US20230192862A1 (en) 2023-06-22
EP4041772A4 (en) 2024-04-24
JP2022553922A (ja) 2022-12-27
CN114555638A (zh) 2022-05-27
JP2025069432A (ja) 2025-04-30
EP4041772A1 (en) 2022-08-17
US20210107982A1 (en) 2021-04-15
JP7634001B2 (ja) 2025-02-20
WO2021068841A1 (en) 2021-04-15
US11466086B2 (en) 2022-10-11

Similar Documents

Publication Publication Date Title
CN114555638B (zh) 结合4-1bb的抗体及其用途
CN111699199A (zh) 结合ox40的抗体及其用途
US10577424B1 (en) Antibodies binding VISTA and uses thereof
JP7505148B2 (ja) Ｌａｇ３に結合する抗体およびその使用
JP2023515223A (ja) Ｉｌ４ｒに結合する抗体とその使用
CN112236455B (zh) 结合pd-1的抗体及其用途
TWI851885B (zh) 結合cd40的抗體及其用途
CN115466327B (zh) 结合tigit的抗体及其用途
WO2023202672A1 (en) Antibodies targeting sirp-alpha and uses thereof
JP7571348B2 (ja) Ｐｄ－１結合抗体及びその用途
WO2021208838A1 (en) Antibodies binding ctla4 and uses thereof
HK40066858B (zh) 结合4-1bb的抗体及其用途
HK40066858A (zh) 结合4-1bb的抗体及其用途
CN121873246A (zh) 结合il6r的抗体及其用途
HK40045182B (en) Antibody binding pd-1 and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066858

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 210031 building 05, accelerator phase IV, No. 122, Huakang Road, Jiangbei new area, Nanjing, Jiangsu Province

Patentee after: Nanjing Weilizibo Biotechnology Co.,Ltd.

Country or region after: China

Address before: Room 711, 7th Floor, Building 3, No. 18 Jialing Jiangdong Street, Jianye District, Nanjing City, Jiangsu Province

Patentee before: NANJING WEI LI ZHI BO BIOTECHNOLOGY Co.,Ltd.

Country or region before: China